CN104208302A - 一种降血脂的金樱子保健口服液及其制备方法 - Google Patents
一种降血脂的金樱子保健口服液及其制备方法 Download PDFInfo
- Publication number
- CN104208302A CN104208302A CN201410424681.4A CN201410424681A CN104208302A CN 104208302 A CN104208302 A CN 104208302A CN 201410424681 A CN201410424681 A CN 201410424681A CN 104208302 A CN104208302 A CN 104208302A
- Authority
- CN
- China
- Prior art keywords
- parts
- rosae laevigatae
- fructus rosae
- radix
- fructus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008280 blood Substances 0.000 title claims abstract description 125
- 210000004369 blood Anatomy 0.000 title claims abstract description 124
- 230000001603 reducing effect Effects 0.000 title claims abstract description 56
- 238000002360 preparation method Methods 0.000 title claims description 21
- 229940100688 oral solution Drugs 0.000 title abstract 3
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 24
- 239000003814 drug Substances 0.000 claims description 97
- 239000007788 liquid Substances 0.000 claims description 61
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 60
- 229940079593 drug Drugs 0.000 claims description 50
- 230000036541 health Effects 0.000 claims description 38
- 238000010438 heat treatment Methods 0.000 claims description 23
- 230000008901 benefit Effects 0.000 claims description 22
- 239000000706 filtrate Substances 0.000 claims description 19
- 230000002829 reductive effect Effects 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 17
- 238000000605 extraction Methods 0.000 claims description 17
- 239000009636 Huang Qi Substances 0.000 claims description 15
- 239000008517 radix Trichosanthis Substances 0.000 claims description 13
- 238000000108 ultra-filtration Methods 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 10
- 238000004659 sterilization and disinfection Methods 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- 241000628997 Flos Species 0.000 claims description 9
- 230000000844 anti-bacterial effect Effects 0.000 claims description 9
- 229920001353 Dextrin Polymers 0.000 claims description 8
- 239000004375 Dextrin Substances 0.000 claims description 8
- 235000019425 dextrin Nutrition 0.000 claims description 8
- 230000001954 sterilising effect Effects 0.000 claims description 8
- 241000238631 Hexapoda Species 0.000 claims description 6
- 241000607479 Yersinia pestis Species 0.000 claims description 6
- 239000012535 impurity Substances 0.000 claims description 6
- 239000004575 stone Substances 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
- 235000012907 honey Nutrition 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 5
- 238000004321 preservation Methods 0.000 claims description 5
- 230000006837 decompression Effects 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 238000004064 recycling Methods 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 235000011837 pasties Nutrition 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 44
- 239000000463 material Substances 0.000 abstract description 16
- 230000017531 blood circulation Effects 0.000 abstract description 13
- 239000000796 flavoring agent Substances 0.000 abstract description 12
- 235000019634 flavors Nutrition 0.000 abstract description 12
- 210000004204 blood vessel Anatomy 0.000 abstract description 11
- 229930182490 saponin Natural products 0.000 abstract description 10
- 150000007949 saponins Chemical class 0.000 abstract description 10
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 10
- 235000014113 dietary fatty acids Nutrition 0.000 abstract description 9
- 229930195729 fatty acid Natural products 0.000 abstract description 9
- 239000000194 fatty acid Substances 0.000 abstract description 9
- 150000004665 fatty acids Chemical class 0.000 abstract description 9
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract description 9
- 201000001320 Atherosclerosis Diseases 0.000 abstract description 7
- 230000008021 deposition Effects 0.000 abstract description 7
- 235000018553 tannin Nutrition 0.000 abstract description 7
- 239000001648 tannin Substances 0.000 abstract description 7
- 229920001864 tannin Polymers 0.000 abstract description 7
- 230000003213 activating effect Effects 0.000 abstract description 5
- 210000002966 serum Anatomy 0.000 abstract description 4
- -1 3-sitosterol Substances 0.000 abstract description 3
- 240000001341 Reynoutria japonica Species 0.000 abstract description 2
- 230000004089 microcirculation Effects 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 241000045403 Astragalus propinquus Species 0.000 abstract 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract 1
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract 1
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract 1
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract 1
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract 1
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract 1
- 240000006509 Gynostemma pentaphyllum Species 0.000 abstract 1
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 abstract 1
- 241000830535 Ligustrum lucidum Species 0.000 abstract 1
- 241000219925 Oenothera Species 0.000 abstract 1
- 235000004496 Oenothera biennis Nutrition 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 229950005143 sitosterol Drugs 0.000 abstract 1
- 235000019197 fats Nutrition 0.000 description 62
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 33
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 31
- 201000010099 disease Diseases 0.000 description 30
- 201000005577 familial hyperlipidemia Diseases 0.000 description 24
- 210000000952 spleen Anatomy 0.000 description 22
- 206010012601 diabetes mellitus Diseases 0.000 description 21
- 206010012735 Diarrhoea Diseases 0.000 description 20
- 230000027939 micturition Effects 0.000 description 20
- 208000002193 Pain Diseases 0.000 description 19
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 18
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
- 230000006870 function Effects 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 16
- 230000001737 promoting effect Effects 0.000 description 16
- 206010011224 Cough Diseases 0.000 description 15
- 230000001276 controlling effect Effects 0.000 description 15
- 235000005911 diet Nutrition 0.000 description 15
- 208000001848 dysentery Diseases 0.000 description 15
- 208000031226 Hyperlipidaemia Diseases 0.000 description 14
- 208000004880 Polyuria Diseases 0.000 description 14
- 230000037213 diet Effects 0.000 description 14
- 230000035619 diuresis Effects 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 230000037396 body weight Effects 0.000 description 13
- 235000012000 cholesterol Nutrition 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 13
- 210000004072 lung Anatomy 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 210000003734 kidney Anatomy 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 206010007247 Carbuncle Diseases 0.000 description 11
- 206010062717 Increased upper airway secretion Diseases 0.000 description 11
- 208000026435 phlegm Diseases 0.000 description 11
- 230000002496 gastric effect Effects 0.000 description 10
- 241000411851 herbal medicine Species 0.000 description 10
- 201000000736 Amenorrhea Diseases 0.000 description 9
- 206010001928 Amenorrhoea Diseases 0.000 description 9
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 9
- 206010020772 Hypertension Diseases 0.000 description 9
- 206010059013 Nocturnal emission Diseases 0.000 description 9
- 229930003268 Vitamin C Natural products 0.000 description 9
- 231100000540 amenorrhea Toxicity 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 9
- 235000017709 saponins Nutrition 0.000 description 9
- 230000028327 secretion Effects 0.000 description 9
- 239000000344 soap Substances 0.000 description 9
- 235000019154 vitamin C Nutrition 0.000 description 9
- 239000011718 vitamin C Substances 0.000 description 9
- 208000008967 Enuresis Diseases 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 241000191967 Staphylococcus aureus Species 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 8
- 230000007812 deficiency Effects 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 208000031971 Yin Deficiency Diseases 0.000 description 7
- 208000006673 asthma Diseases 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 238000005728 strengthening Methods 0.000 description 7
- 210000002700 urine Anatomy 0.000 description 7
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 206010027514 Metrorrhagia Diseases 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- 206010037660 Pyrexia Diseases 0.000 description 6
- 206010042674 Swelling Diseases 0.000 description 6
- 210000001015 abdomen Anatomy 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 6
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 6
- 210000001124 body fluid Anatomy 0.000 description 6
- 239000010839 body fluid Substances 0.000 description 6
- 235000015165 citric acid Nutrition 0.000 description 6
- 208000029078 coronary artery disease Diseases 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 235000011090 malic acid Nutrition 0.000 description 6
- 239000001630 malic acid Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 231100000614 poison Toxicity 0.000 description 6
- 210000000582 semen Anatomy 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 230000035922 thirst Effects 0.000 description 6
- 208000006820 Arthralgia Diseases 0.000 description 5
- 206010010774 Constipation Diseases 0.000 description 5
- 206010013935 Dysmenorrhoea Diseases 0.000 description 5
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 5
- 230000001142 anti-diarrhea Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000004209 hair Anatomy 0.000 description 5
- 201000001421 hyperglycemia Diseases 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 206010003210 Arteriosclerosis Diseases 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 208000005171 Dysmenorrhea Diseases 0.000 description 4
- 208000004930 Fatty Liver Diseases 0.000 description 4
- 208000015220 Febrile disease Diseases 0.000 description 4
- 229930091371 Fructose Natural products 0.000 description 4
- 239000005715 Fructose Substances 0.000 description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 4
- 206010019708 Hepatic steatosis Diseases 0.000 description 4
- 206010023126 Jaundice Diseases 0.000 description 4
- 208000019255 Menstrual disease Diseases 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 4
- 208000005392 Spasm Diseases 0.000 description 4
- 244000269722 Thea sinensis Species 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 description 4
- 239000003212 astringent agent Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000007599 discharging Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 208000010706 fatty liver disease Diseases 0.000 description 4
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 4
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 4
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 4
- 229960002733 gamolenic acid Drugs 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 210000004347 intestinal mucosa Anatomy 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 239000002574 poison Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 230000003014 reinforcing effect Effects 0.000 description 4
- 229910052711 selenium Inorganic materials 0.000 description 4
- 239000011669 selenium Substances 0.000 description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 239000011573 trace mineral Substances 0.000 description 4
- 235000013619 trace mineral Nutrition 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- 230000002087 whitening effect Effects 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 206010000077 Abdominal mass Diseases 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 3
- 241001672694 Citrus reticulata Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 206010019909 Hernia Diseases 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 206010040943 Skin Ulcer Diseases 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 206010041497 Spermatorrhoea Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 206010043458 Thirst Diseases 0.000 description 3
- 208000009205 Tinnitus Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000003143 atherosclerotic effect Effects 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 239000000812 cholinergic antagonist Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 208000001780 epistaxis Diseases 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 206010061989 glomerulosclerosis Diseases 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 208000035861 hematochezia Diseases 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 235000003642 hunger Nutrition 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 3
- 239000002366 mineral element Substances 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001047 pyretic effect Effects 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 206010040872 skin infection Diseases 0.000 description 3
- 231100000019 skin ulcer Toxicity 0.000 description 3
- 230000002048 spasmolytic effect Effects 0.000 description 3
- 210000005070 sphincter Anatomy 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 231100000886 tinnitus Toxicity 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 208000004611 Abdominal Obesity Diseases 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 244000075440 Catunaregam spinosa Species 0.000 description 2
- 206010065941 Central obesity Diseases 0.000 description 2
- 206010008132 Cerebral thrombosis Diseases 0.000 description 2
- 208000034656 Contusions Diseases 0.000 description 2
- 206010013954 Dysphoria Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 208000015924 Lithiasis Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 description 2
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 206010053615 Thermal burn Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 206010047531 Visual acuity reduced Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 208000034526 bruise Diseases 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001840 cholesterol esters Chemical class 0.000 description 2
- 230000027326 copulation Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 230000007937 eating Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 239000008929 jingui shenqi Substances 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 210000004914 menses Anatomy 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 229940100243 oleanolic acid Drugs 0.000 description 2
- 235000021313 oleic acid Nutrition 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000021147 sweet food Nutrition 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- HTIQEAQVCYTUBX-KRWDZBQOSA-N (S)-amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-KRWDZBQOSA-N 0.000 description 1
- JKBKMIKSUBLJRK-UHFFFAOYSA-N 2-propylsulfanylpyrimidine Chemical compound CCCSC1=NC=CC=N1 JKBKMIKSUBLJRK-UHFFFAOYSA-N 0.000 description 1
- 244000252230 Artemisia stelleriana Species 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000221377 Auricularia Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241001050985 Disco Species 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 102100036721 Insulin receptor Human genes 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- 235000001715 Lentinula edodes Nutrition 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 208000000501 Lipidoses Diseases 0.000 description 1
- 206010024585 Lipidosis Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- QYZBCWXZSYTIOY-UHFFFAOYSA-N Mercuric oxide Chemical compound [O-2].[Hg+2] QYZBCWXZSYTIOY-UHFFFAOYSA-N 0.000 description 1
- 208000002038 Muscle Hypertonia Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000013901 Nephropathies and tubular disease Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 235000011158 Prunus mume Nutrition 0.000 description 1
- 244000018795 Prunus mume Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038001 Rebound effect Diseases 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- 241000405911 Rehmannia glutinosa Species 0.000 description 1
- 206010038372 Renal arteriosclerosis Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000657665 Rhopilema esculentum Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 101000693619 Starmerella bombicola Lactone esterase Proteins 0.000 description 1
- 206010042170 Strangury Diseases 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010048245 Yellow skin Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 231100000132 chronic toxicity testing Toxicity 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008162 cooking oil Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- MDZKJHQSJHYOHJ-UHFFFAOYSA-N crataegolic acid Natural products C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MDZKJHQSJHYOHJ-UHFFFAOYSA-N 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 208000024756 faint Diseases 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229960003499 fenofibrate micronized Drugs 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 210000002601 glomerular mesangium Anatomy 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 235000020997 lean meat Nutrition 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229950008554 levamlodipine Drugs 0.000 description 1
- 208000013433 lightheadedness Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 235000021142 long-term diet Nutrition 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 235000014659 low sodium diet Nutrition 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- MDZKJHQSJHYOHJ-LLICELPBSA-N maslinic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MDZKJHQSJHYOHJ-LLICELPBSA-N 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 229960004329 metformin hydrochloride Drugs 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 230000008965 mitochondrial swelling Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- NIFIFKQPDTWWGU-UHFFFAOYSA-N pyrite Chemical class [Fe+2].[S-][S-] NIFIFKQPDTWWGU-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 230000001739 rebound effect Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 230000036578 sleeping time Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000005982 spleen dysfunction Effects 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 150000003673 urethanes Chemical class 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009978 visual deterioration Effects 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000002918 waste heat Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种降血脂的金樱子保健口服液,其所述保健口服液原料药的重量份数比为:金樱子10~50份,天花粉10~20份,山楂10~20份,蒲黄10~20份、冬瓜皮10~20份、蒲黄10~20份,月见草10~20份,生地10~20份、女贞子10~20份、虎杖10~20份、制首乌10~20份、绞股蓝10~20份、黄芪10~20份、茯苓10~20份、赤芍10~20份、陈皮10~20份、丹参10~20份。金樱子中含有脂肪酸、卜谷省醇、躁质及皂式等,能降低血脂,减少脂肪在血管内的沉积,可用于治疗动脉粥样硬化症。再加上一些活血化瘀,对脂肪和血清甘油三酯均有明显降低作用的中药材,且能改善微循环,这些药材大多口感清淡,不影响金樱子口味,使人易于接受,更能较好的达到降血脂的功效。
Description
技术领域
本发明涉及含有来源于植物、动物或矿物原料的医用保健品,特别涉及一种降血脂的金樱子保健口服液及其制备方法。
背景技术
随着生活水平的提高,人们的饮食状况也发生了改变,高血脂已经成为一种十分常见的疾病,同时高血脂的出现又会导致更多的其他疾病,如高血压等。因此,怎样才能降血脂已经成为众人最关心的问题。由于经济的日益发达,现代人生活水平的不断提升,致使人们过多的热爱享受,不注意自己的生活方式、行为习惯、饮食嗜好,从而引起的疾病。快节奏的社会生活,激烈竞争的工作压力,对现代人的身心健康造成了严重的威胁,使半数以上的人处于亚健康状态,表现为:头晕、心慌、乏力、食欲不振、记忆力减退、失眠、对事无兴趣等,加之,长期的饮食不合理,即:精粮完全取代粗粮,大量的三高(高热、高蛋白、高脂肪)、三多(防腐剂多、增味剂多、激素多)食物的摄入和食物中残留的农药、化肥在体内的存积,再加上空气、水源污染和运动量偏小,这样长期下去会使三高症(高血压、高血糖、高血脂)、心脑血管疾病、癌症等所谓的“现代文明病”急速上升,而且不断年轻化,严重的危害到人类的健康和生命。“三高症”是指高血压、高血糖(糖尿病)和高血脂症。通常伴随着肥胖。它们是现代社会所派生出来的“富贵病”,可以单独存在,也可能相互关联。如:糖尿病人很容易同时患上高血压或高血脂症,而高血脂又是动脉硬化形成和发展的主要因素,动脉硬化患者血管弹性差加剧血压升高,所以后期都形成了“三高症”。关于三高是什么有资料统计,在中国人的十大死亡原因中,与代谢疾病相关的死亡率就高达35.7%,与“三高”相关的死亡人数也占总死亡人数的27%。高血脂可以引起血管栓塞;高血压可以引起脑出血和脑血管破裂;高血糖可以引起糖尿病。
世界卫生组织曾经明确提出,防止心血管病的第一道防线就是减少“三高”和控制“三高”。很多糖尿病人都伴有高脂血症,因此人们通常把糖尿病与高脂血症称为姐妹病,并认为高血脂是糖尿病的继发症。据统计大约40%的糖尿病病人有脂代谢紊乱。其特点是甘油三酯增高和高密度脂蛋白降低。糖尿病引起血脂增高的原因是由于糖尿病人胰岛素不足时,体内脂酶活泼性是减低的,因此容易血脂增高。另一方面糖尿病本身除糖代谢紊乱外同时还伴脂肪、蛋白质和水、电介质的紊乱。经常有游离脂肪酸从脂肪库中动员出来,使血中甘油三酯及游离脂肪酸浓度增高。再一方面2型糖尿病人进食过多,运动少,促使体内脂类合成增多,这也是造成血脂增高的原因。而肥胖伴高血脂者,由于胰岛素受体数相对减少,从而产生胰岛素抵抗,易诱发糖尿病。血脂增高者还易引起心、脑血管并发症。
金樱子别名糖罐子、山石榴。属蔷薇科植物。中国中、南部各省都有分布。其果实酸甜可食,并可以熬糖或酿酒。根、叶、花、果均供药用。金樱子含丰富的糖类(果糖、蔗糖)和柠檬酸、苹果酸、鞣质、维生素C等成分。味甘、微酸、涩,性平。能固精缩尿,涩肠止泻。口服果实能促进胃液分泌,帮助消化,且对肠粘膜有收敛作用,减少分泌,制止腹泻。煎剂对金黄色葡萄球菌、大肠杆菌、绿脓杆菌、痢疾杆菌等有抑制作用。能降低实验动物血清胆固醇,减轻动脉粥样硬化的程度。
金樱子果实风味独特,有蜂蜜味和幽香,其营养极丰富,内含糖(主要是果糖等还原糖)、柠檬酸、苹果酸、鞣质、维生素、20余种氨基酸,18种矿物元素以及树脂、皂甙等成份,尤以维生素C和还原糖含量较高。据测定,每100g鲜金樱子果肉含维生素C1009mg,含量仅次于刺梨,是鲜枣的2倍,弥猴桃的10倍,柑桔的30倍。其次,金樱子含有丰富的锌和硒,这两种元素为人体必需的具有特定保健和防癌功效的微量元素。
现代药理证明:金樱子果实口服既能促进胃液分泌帮助消化,又能使肠粘膜收缩,分泌减少而止泻;金樱子煎液对金黄色葡萄球菌、大肠杆菌、绿脓杆菌、痢疾杆菌及流感病毒均有较强的抑制作用。1、固精缩尿,涩肠止泻。金樱子中含有大量的酸性物质、皂成等,既能固精室防止男子遗精滑泄、女子带下过多,又能涩肠道,防止脾虚约束不力所致的泻痢。2、缩尿止遗。金樱子中含有大量的酸性物质和皂甙,具有制约膀脱括约肌,延长排尿时间间隔,增加每次排出尿量的作用,可用于治疗遗尿及小便频数之症。3、止咳平喘,抗痉挛。中医认为,喘咳多由肺气上逆而致,金樱子味酸涩,能敛肺气,可止咳平喘。现代研究发现,金樱子中含有抗平滑肌痉挛的成分,可防止胃肠及气管的痉挛。4、降血脂。金樱子中含有脂肪酸、卜谷省醇、躁质及皂式等,能降低血脂,减少脂肪在血管内的沉积,可用于治疗动脉粥样硬化症。5、抗菌消炎。研究发现,金樱子提取液可杀死金黄色葡萄球菌及大肠杆菌等,可用来治疗因金葡菌或大肠杆菌感染而致的疾病。金樱子含柠檬酸、苹果酸、维生素C、皂甙和丰富的糖类。金樱子性味酸涩平,具有固精涩肠、缩尿止泻的功效。治滑精、遗尿、小便频数、脾虚泻痢、肺虚喘咳、自汗盗汗、崩漏带下等,《蜀本草》载“治脾泄下痢,止小便利,涩精气”。《滇南本草》载“治日久下痢,血崩带下,涩精遗泄”。有实火、邪热煮忌食。
中药气味清苦,很多人不愿长期服用;即使服用,是药三分毒,让人长期服用时也产生抗拒心理。怎么把金樱子的功效发挥到最大又不伤害人体,并且明显改善口感,使人能接受,是我们迫切需要解决的问题。金樱子里面含有大量安全有效的活性物质保健品,能大大降糖降脂,一直是人们期待解决问题的关键。金樱子中含有脂肪酸、卜谷省醇、躁质及皂式等,能降低血脂,减少脂肪在血管内的沉积,可用于治疗动脉粥样硬化症。现在市场迫切需要开发一种无毒、能被生物体完全吸收,降血脂的金樱子保健品。
发明内容
本发明所要解决的技术问题在于,目前西医对糖尿病高脂血症的研究和治疗已取得较大的成果,但长期用药所引起的肝肾功能、消化道症状,肌肉损害及停药后反跳作用仍是治疗的难题。鉴于中医具有辩证论治的特色,中药有毒副作用小的优势,中药保健治疗引起广泛关注。中药存在着双向调节作用,当中药浓度过高时,可能引起某种拮抗作用,而使药效受影响;低剂量时,可能药物浓度过低,致药效不显。并且服用起来口感不佳,药物清苦,很不方便。金樱子中含有脂肪酸、卜谷省醇、躁质及皂式等,能降低血脂,减少脂肪在血管内的沉积,可用于治疗动脉粥样硬化症。
为解决上述技术问题,本发明提供一种降血脂的金樱子保健口服液,其所述保健口服液原料药的重量份数为:金樱子10~50份,天花粉10~20份,山楂10~20份,蒲黄10~20份、冬瓜皮10~20份、蒲黄10~20份,月见草10~20份,生地10~20份、女贞子10~20份、虎杖10~20份、制首乌10~20份、绞股蓝10~20份、黄芪10~20份、茯苓10~20份、赤芍10~20份、陈皮10~20份、丹参10~20份。
所述降血脂的金樱子保健口服液,其所述保健口服液原料药的重量份数可以为:金樱子10~30份,天花粉10~15份,山楂10~15份,蒲黄10~15份、冬瓜皮10~15份、蒲黄10~15份,月见草10~15份,生地10~15份、女贞子10~15份、虎杖10~20份、制首乌10~20份、绞股蓝10~20份、黄芪10~20份、茯苓10~20份、赤芍10~20份、陈皮10~20份、丹参10~20份。
所述降血脂的金樱子保健口服液,其所述保健口服液原料药的重量份数还可以为:金樱子10~40份,天花粉10~20份,山楂10~20份,蒲黄10~20份、冬瓜皮10~20份、蒲黄10~20份,月见草10~20份,生地10~20份、女贞子10~20份、虎杖10~15份、制首乌10~15份、绞股蓝10~15份、黄芪10~15份、茯苓10~15份、赤芍10~15份、陈皮10~15份、丹参10~15份。
为解决上述技术问题,本发明还提供一种降血脂的金樱子保健口服液的制备方法,其所述中药保健口服液的制备步骤包括:
a.金樱子的制备,作为组分1;
b.将所述其余原料药放入乙醇中加热回流提取2次,作为组分2;
c.将上述两种提取液组分1和组分2合并,浓缩后加糊精调和,消毒杀菌后制备成保健口服液剂。
所述步骤a中,可以选取成熟度高,无虫害,无腐烂,无杂物的金樱子果实;分选时,选出其中的杂质,泥土石块,用振动筛和水洗槽进行分选;金樱子果质硬,采用大滚距压式的破碎机,将金樱子外皮挤破而不破碎果实的核,然后将其果核泡入60度以上的白酒或食用酒精中10-15天。
所述步骤a中,可以进一步包括,将浸泡好的金樱子果核加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.36的浸膏,加热浓缩至膏状,静置备用,成组分1。
所述步骤b中,可以将其余原料药的药放入10倍量乙醇中,浸泡1-2小时,加热提取2次,每次1-2小时,合并提取液,静置后去上清液,然后放入减压浓缩罐内,减压回收乙醇,浓缩至药液浓度为0.6g生药/mL,抽滤至滤液的相对密度为20℃时1.06的浸膏,成为组分2。
所述步骤c中,可以将组分1和组分2合并后,置入双效真空浓缩器中,浓缩至90℃时相对密度为1.05的浓缩液,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,滤液再置入双效真空浓缩器中,浓缩至每1ml含1g生药量;浓缩后的膏剂加糊精调和,紫外线消毒杀菌后装瓶。
为解决上述技术问题,本发明也提供一种降血脂的金樱子保健口服液的制备方法,其制备步骤还可以为:
a.金樱子的制备,作为组分1;
b.将所述其余原料药加水浸泡、提取3次作为组分2;
c.将组分1和组分2混合,浓缩后加适量蜂蜜调和,紫外线消毒杀菌后装瓶。
所述步骤b中,可以将其余原料药浸泡水中12小时,然后放入提取罐加热煮沸1小时,过滤,滤液备用;滤渣加水,第二次加热,煮沸45分钟,过滤,滤液备用;滤渣再加水,第三次加热煮沸半小时,过滤;将三次滤液合在一起,用纱布过滤,残渣中加入50-60%乙醇,60℃-70℃继续浸提2h,每10min搅拌一次,纱布过滤,合并浸提液,浓缩成糊状成为组分2。
金樱子中含有脂肪酸、卜谷省醇、躁质及皂式等,能降低血脂,减少脂肪在血管内的沉积,可用于治疗动脉粥样硬化症。汤剂是中医的传统剂型,具有方便随症加减等优点,但汤剂煎煮、携带、使用不方便,且成分煎出不完全,口感差,不适合现代人群用药习惯。由于本发明主要用于防治高脂血症,高血糖,该病属于多因素相关的慢性疾病,病程较长,需长期用药才能达到良好的效果,故应选择服用、携带、使用方便保健茶式饮品更能提高保健作用。再加上一些活血化瘀,对脂肪和血清甘油三酯均有明显降低作用的中药材,且能改善微循环,这些药材大多口感清淡,不影响金樱子口味,使人易于接受,更能较好的达到降血脂的功效。
具体实施方式
人的血液中,血浆内所含的脂类称为血脂,包括胆固醇、胆固醇脂、甘油三脂、磷脂和未脂化的脂酸等数种。当胆固醇、甘油三脂等均超过正常值时,则统称为高脂血症。高脂血症是动脉粥样硬化的主要发病因素。常因侵犯重要器官而引起严重的后果,如冠心病、糖尿病、脑血管意外、顽固性高血压及肾病综合症、胰腺炎、结石症、脂肪肝等。动脉硬化的发生和发展,与血脂过高有着密切的关系。养生指南:一.合理饮食调养:人体脂类包括脂肪和类脂两种。高脂血症与饮食的关系最为密切。人体脂肪的积聚和部分类脂的来源,主要来自饮食。只有一部分类脂是在体内合成的,称为内生性类脂。控制饮食对高脂血症的防治是十分重要的。饮食提倡清淡,基本吃素。但不宜长期吃素,否则饮食成分不完善,反而可引起内生性胆固醇增高。宜限制高脂肪、高胆固醇类饮食,如动物脑髓、蛋黄、鸡肝、黄油等。脂肪摄入量每天限制在30~50克。糖类食品也要限制,不吃甜食和零食。多吃蔬菜和水果。宜低盐饮食,食油宜用豆油、花生油、菜油、麻油等。饥饱适度,每餐进食量以下一餐就餐前半小时有饥饿感为度,不宜采用饥饿疗法,过度的饥饿反而使体内脂肪加速分解,使血中脂酸增加。二.绝对戒烟忌酒:香烟中的尼古丁,能使周围血管收缩和心肌应激性增加,使血压升高,心绞痛发作。不适当饮酒能使心功能减退,对胃肠道、肝脏、神经系统、内分泌系统均有损害,应绝对戒烟忌酒。三.提倡适量饮茶:茶叶中含有的儿茶酸有增强血管柔韧性、弹性和渗透性的作用,可预防血管硬化。茶叶中的茶碱和咖啡碱能兴奋精神,促进血液循环,减轻疲劳和具有利尿作用。适量饮茶能消除油腻饮食而减肥。但过多喝浓茶,会刺激心脏,使心跳加快,对身体有害。四.适当运动减肥:控制肥胖是预防血脂过高的重要措施之一。除饮食控制外,提倡坚持体育锻炼,如慢跑、五禽戏、太极拳、打乒乓球、老年迪斯科等。平时经常参加体力劳动。要控制体重的增长。
高脂血症对病人有哪些危害?(1)肾小球硬化等:高脂血症可引起血管内皮细胞损伤和灶状脱落,导致血管壁通透性升高,血浆脂蛋白得以进入并沉积于血管壁内膜,其后引起巨噬细胞的清除反应和血管平滑肌细胞增生并形成斑块,而导致动脉硬化,肾动脉硬化、管腔狭窄,可使肾脏发生缺血、萎缩、间质纤维增生。若肾血管阻塞则相应区域梗死,梗死灶机化后形成瘢痕。如此导致肾小球硬化。在肾外则可加速冠状动脉硬化的发生,导致冠心病和增加患者发生心肌梗塞的危险性。同样,其他部位的动脉硬化则致相应的疾病,如脑动脉硬化、脑梗塞等。(2)肾小球损伤:高脂血症可引起脂质在肾小球内沉积,低密度脂蛋白可激活循环中单核细胞并导致肾小球内单核细胞浸润,而引起或加重炎症反应,同时肾小球的系膜细胞、内皮细胞均能产生活化氧分子,促进脂质过氧化,氧化的低密度脂蛋白(OX-LDL)具有极强的细胞毒作用,导致肾组织损伤。另外,高脂血症还能引起肾小球系膜基质中胶原、层粘连蛋白及纤维蛋白增加,这些成分均与肾小球硬化直接相关。
减肥有助于降血脂吗?众所周知,高脂血症和低HDL血症是动脉硬化最危险的因子之一,而肥胖者常常合并脂代谢的异常,并随着肥胖程度的增加,高脂血症越表现明显;相反,过高的血脂,也同时促进脂肪的过度积累,形成恶性循环。不仅如此,人们还发现血脂的升高与脂肪的分布状态有密切的关系。基塞伯等(Kissebah,AH)等人认为:“根据人的脂肪分布进行分类,可分为有体干脂肪沉着显著的中心性肥胖,四肢明显的末稍性肥胖;还有上半身脂肪堆积较多的上半身肥胖和下半身脂肪堆积较多的下半身肥胖。高脂血症和糖尿病等病,以中心性肥胖和上半身肥胖为主,故而积极地采取措施进行减肥,有助于降低血脂。减肥降脂应以综合疗法为主,包括使用中药利湿化痰剂,限制吃高脂肪的饮食,多吃蔬菜,豆制品,瘦肉、鸡肉、海蜇等,尽可能地多吃含纤维素较多的蔬菜,可以减少肠内胆固醇的吸收,洋葱、大蒜、木耳、山楂、香菇都有较好的降脂作用,炒菜用油最好以植物油为主。限制病人的饮食热量,少食甜食,加强运动,增加消耗,戒烟酒,避免过度紧张,生活要有规律,选用降脂药物如脉通、益寿宁、月见草油丸等,平素常饮泽泻汤(泽泻10g、干荷叶一张)能保持较好疗效,同时也减少了诱发其他疾病的危险。。
金樱子为蔷薇科植物金樱子的果实,又称山石榴、刺梨子等。金樱子是一味补肾的名药。中医认为,金樱子味酸,性平,入肾、大肠二经,有固精涩肠,缩尿止泻的功效。可以治疗遗精滑精,尿频遗尿,带下,崩漏,自汗,盗汗,肺虚咳嗽,脾虚泻痢等。现代药理学研究证实:金樱子提取物可延长排尿间隔时间;所含鞣质对金黄色葡萄球菌、大肠杆菌、绿脓杆菌等有较强的抑制作用。
金樱子果实风味独特,有蜂蜜味和幽香,其营养极丰富,内含糖(主要是果糖等还原糖)、柠檬酸、苹果酸、鞣质、维生素、20余种氨基酸,18种矿物元素以及树脂、皂甙等成份,尤以维生素C和还原糖含量较高。据测定,每100g鲜金樱子果肉含维生素C1009mg,含量仅次于刺梨,是鲜枣的2倍,弥猴桃的10倍,柑桔的30倍。其次,金樱子含有丰富的锌和硒,这两种元素为人体必需的具有特定保健和防癌功效的微量元素。
现代药理证明:金樱子果实口服既能促进胃液分泌帮助消化,又能使肠粘膜收缩,分泌减少而止泻;金樱子煎液对金黄色葡萄球菌、大肠杆菌、绿脓杆菌、痢疾杆菌及流感病毒均有较强的抑制作用。1、固精缩尿,涩肠止泻。金樱子中含有大量的酸性物质、皂成等,既能固精室防止男子遗精滑泄、女子带下过多,又能涩肠道,防止脾虚约束不力所致的泻痢。2、缩尿止遗。金樱子中含有大量的酸性物质和皂甙,具有制约膀脱括约肌,延长排尿时间间隔,增加每次排出尿量的作用,可用于治疗遗尿及小便频数之症。3、止咳平喘,抗痉挛。中医认为,喘咳多由肺气上逆而致,金樱子味酸涩,能敛肺气,可止咳平喘。现代研究发现,金樱子中含有抗平滑肌痉挛的成分,可防止胃肠及气管的痉挛。4、降血脂。金樱子中含有脂肪酸、卜谷省醇、躁质及皂式等,能降低血脂,减少脂肪在血管内的沉积,可用于治疗动脉粥样硬化症。5、抗菌消炎。研究发现,金樱子提取液可杀死金黄色葡萄球菌及大肠杆菌等,可用来治疗因金葡菌或大肠杆菌感染而致的疾病。
山楂含多种维生素、山楂酸、酒石酸、柠檬酸、苹果酸等,还含有黄酮类、内酯、糖类、蛋白质、脂肪和钙、磷、铁等矿物质,所含的解脂酶能促进脂肪类食物的消化。促进胃液分泌和增加胃内酶素等功能。中医认为,山楂具有消积化滞、收敛止痢、活血化淤等功效。主治饮食积滞、胸膈痞满、疝气血淤闭经等症。山楂中含有山萜类及黄铜类等药物成分,具有显著的扩张血管及降压作用,有增强心肌、抗心律不齐、调节血脂及胆固醇含量的功能,山楂有活血化淤的功效,有助于解除局部淤血状态,对跌打损伤有辅助疗效;山楂所含的黄酮类和维生素C、胡萝卜素等物质能阻断并减少自由基的生成,能增强机体的免疫力,有防衰老、抗癌的作用;山楂中有平喘化痰、抑制细菌、治疗腹痛腹泻的成分。
天花粉为葫芦科植物栝蒌的根,是一种中药,为清热泻火类药物,其具体功效是清热泻火,生津止渴,排脓消肿。主治:治热病口渴、消渴、黄疸、肺燥咳血、痈肿、痔痿。对于治疗糖尿病,常用它与滋阴药配合使用,以达到标本兼治的作用。《本草汇言》:天花粉,退五脏郁热,如心火盛而舌干口燥,肺火盛而咽肿喉痹,脾火盛而口舌齿肿,痰火盛而咳嗽不宁。若肝火之胁胀走注,肾火之骨蒸烦热,或痈疽已溃未溃,而热毒不散,或五疸身目俱黄,而小水若淋若涩,是皆火热郁结所致,惟此剂能开郁结,降痰火,并能治之。又其性甘寒,善能治渴,从补药而治虚渴,从凉药而治火渴,从气药而治郁渴,从血药而治烦渴,乃治渴之要药也。
蒲黄味甘、微辛;性平。归肝;心;脾经。功效止血;祛瘀;利尿。功效分类:凉血止血药;活血祛瘀药。主治:吐血;咯血;衄血;备痢;便血;崩漏;外伤出血;心腹疼痛;经闭腹痛;产后瘀痛;痛经;跌扑肿痛;血淋涩痛;带下;重舌;口疮;聤耳;阴下湿痒。蒲黄能防止喂饲高脂动物的血清胆固醇水平增高,并能增加喂饲高脂家兔的粪便胆固醇。该作用除抑制肠道吸收胆固醇、增加粪便胆固醇外,可能还与影响体内胆固醇代谢有关。将蒲黄油、蒲黄残渣及蒲黄花粉分别喂饲食饵性高胆固醇血症家兔,结果蒲黄花粉的降血脂作用最为明显。给饲以高脂饲料的家兔每日每只加服蒲黄16g,12周后停饲高脂,继续服用蒲黄4周,给药组不仅血清胆固醇迅速下降,9周即达正常浓度,而且主动脉壁胆固醇含量减少,病变减轻。心肌内小动脉扩张,血流增加,代谢旺盛,心肌营养改善,斑块形成较少;电镜检查,可见多数兔主动脉内皮完整光滑,内膜下层正常,仅偶见极少量的细胞浸润和脂质沉积。
冬瓜皮:性味:味甘;性微寒。归经:归肺经;脾经;小肠经。功能:清热利水;消肿。主治:水肿;小便不利;泄泻;疮肿利尿作用:非肾性水肿恢复期患者内服冬瓜皮煎剂2两,并饮水1000ml,在服药后2小时内排出尿量较对照组显著增加,2-4小时之间,则较对照组减少。人体试验,该品62g煎至于100ml口服,另以水100ml作自身对照,证明有利尿作用。.水肿。本品味甘,药性平和,善于利水消肿。用于治水肿.《本草图经》:功用与冬瓜等。《滇南本草》:止渴,消痰,利小便。治中风。《纲目》:主驴马汗入疮肿痛,阴干为末涂之,又主折伤损痛。《本草再新》:走皮肤,去湿追风,补脾泻火。
月见草:它是本世纪发现的最重要的营养药物。可治疗多种疾病,调节血液中类脂物质,对高胆固醇、高血脂引起的冠状动脉梗塞、粥样硬化及脑血栓等症有显著疗效。月见草性温,味甘。有强筋壮骨、祛风除湿的功能,用于治疗风湿病,筋骨疼痛等症。其种子经过榨油、皂化、酸化可先先获得γ-亚麻酸,以此为原料,经过化学结构改造,再经过生物合成即可得到前列腺素E1,它是抗血栓、扩血管新药,广泛用于血栓性脉管炎、慢性动脉闭塞症、心肌梗塞、视网膜中央静脉血栓动脉造影、血管重建造影等。月见草含月桂酸、肉豆蔻酸、棕榈酸、硬脂酸、花生素、辛酸等成分。其种子所榨提的油,称为月见草油。主要成分为油酸、亚油酸、γ-亚麻酸等。γ-亚麻酸是人体所必需的高级不饱和脂肪酸。花中含挥发油及萜类成分。叶与茎中富含维生素C、多种黄酮甙生物碱及1%~17%的单宁酸。不同种的草籽含油量在15%~25%。油中除含有棕榈酸、油酸、亚油酸、硬脂酸以外,γ-亚麻酸含量在7%~10%。因而月见草油具有很明显的功能特性。月见草油及其制成品在治疗高血压、预防脑血栓、降脂、降糖、抗衰老等方面有广泛的医用、药用价值。
生地:生地也叫生地黄,玄参科多年生草本植物地黄Rehmannia glutinosaLibosch.的新鲜或干燥的块根。清热、生津、润燥、滑肠、破瘀、生新、止痛、调经、金疮瘀、凉血、止血;鲜地黄和生地黄的作用是有所不同的。鲜地黄清热生津,可以止血和凉血,经常是用于热病伤阴,吐血、咽喉肿痛、舌绛烦渴、发斑发疹以及衄热等病症。相对于鲜地黄,生地黄是凉血清热,也可以生津,还可以养阴,多用于治疗阴虚内热、骨蒸劳热、舌绛烦渴、发斑发疹等问题。生地性寒,功能为滋阴补肾。不只生津止渴和凉血清热,还对血崩、月经不调、胎动不安、便秘等有作用,凡是血分有热伤阴的人,都可以经常服用。如果想要治疗温热病,可以用生地做清营汤;如果是治疗温病的后期,由于余热还没消尽,应该把生地用来煮青蒿鳖甲汤;另外,针对血热毒盛,斑疹紫黑,温热病严重热入营血的症状,可以服用生地制成的四生丸;一般要养阴生津来治疗内热消渴和便秘的,应该食用生地煮的曾液汤。
女贞子用于肝肾阴虚的目暗不明,视力减退,须发早白,腰酸耳鸣及阴虚发热等。本品能补肝肾阴,但药力平和,须缓慢取效。治目暗不明,常配熟地,枸杞等同用,治须发早白,常配桑葚同用,阴虚发热,常配地骨皮。肝肾阴虚,头昏目眩、遗精耳鸣、腰膝酸软,须发早白,冠心病、高脂血症、高血压、慢性肝炎。对肝脏的保护作用研究认为,女贞子含有齐墩果酸,给大鼠皮下注射,可降低血清谷丙转氨酶,对四氯化碳诱发的肝损伤有明显保护作用,并能促进肝细胞再生.齐墩果酸亦可使肝内甘油三酯蓄积减少、肝细胞变性坏死明显减轻、糖原蓄积增加、血清γ球蛋白下降;超微结构可见肝细胞内线粒体肿胀与内质网囊泡变性减轻、肝组织间质炎症反应减弱
虎杖微苦,微寒。归肝、胆、肺经。功能与主治:清热解毒,利胆退黄,祛风利湿,散瘀定痛,止咳化痰。用于关节痹痛,湿热黄疸,经闭,产后瘀血不下,癞瘕,咳嗽痰多,水火烫伤,跌打损伤,痈肿疮毒。虎杖提取物有解热镇痛作用。白黎芦醇甙与戊巴比妥钠及氨基甲酸乙酯有协同作用,能明显延长小鼠睡眠时间。虎杖煎剂对烫伤创面有收敛、防止感染和消炎作用。此外,一定浓度的大黄素可引起小肠肌张力增高,收缩振幅增大,增大剂量则可抑制小肠活动。《本草拾遗》:主风在骨节间及血瘀。煮汁作酒服之。《日华子本草》:治产后恶血不下,心腹胀满。排脓,主疮疖痈毒,妇人血晕,扑损瘀血,破风毒结气。《滇南本草》:攻诸肿毒,止咽喉疼痛,利小便,走经络。治五淋白浊,痔漏,疮痈,妇人赤白带下。
绞股蓝经现代医学研究发现,绞股蓝主要有效成分为多糖类、黄酮类、皂苷类及微量元素类,其功效主要是促进人体脂肪类物质代谢、营养人体细胞,同时具有不错的解毒消炎作用,广泛应用于高血脂、脂肪肝、肥胖、便秘、失眠、乙肝、慢性呼吸道炎症(咽喉炎、肠胃炎等)的治疗与保健。
丹参苦,微寒。归心、肝经。祛瘀止痛,活血通经,清心除烦。用于月经不调,经闭痛经,症瘕积聚,胸腹刺痛,热痹疼痛,疮疡肿痛,心烦不眠。用于胸肋胁痛,风湿痹痛,症瘕结块,疮疡肿痛,跌仆伤痛,月经不调,经闭痛经,产后瘀痛等。治疗胸肋疼痛、症瘕结块,以及月经不调、经闭经痛具有良效。《纲目》载:丹参,按《妇人明理论》云,四物汤治妇人病,不问产前产后,经水多少,皆可通用,惟一味丹参散,主治与之相同。盖丹参能破宿血,补新血,安生胎,落死胎,止崩中滞下,调经脉。丹参主要成分丹参酮有扩张血管、改善循环、解除血管内凝血等作用,具有活血化痕之功效,并能促进肝脏血液循环,利于肝细胞再生。
黄芪具有补气固表、利水退肿、托毒排脓、生肌等功效。黄芪的药用迄今已有2000多年的历史,现代研究,黄芪含皂甙、蔗糖、多糖、多种氨基酸、叶酸及硒、锌、铜等多种微量元素。有增强机体免疫功能、保肝、利尿、抗衰老、抗应激、降压和较广泛的抗菌作用。但表实邪盛,气滞湿阻,食积停滞,痈疽初起或溃后热毒尚盛等实证。黄芪具有补气固表,利尿托毒,排脓,敛疮生肌的功效。用于气虚乏力,食少便溏,中气下陷,久泻脱肛,便血崩漏,表虚自汗,痈疽难溃,久溃不敛,血虚萎黄,内热消渴。《本经》记载:“主痈疽,久败疮,排脓止痛。补虚,小儿百病。”《日华子本草》记载:“助气壮筋骨,长肉补血。”
茯苓味甘、淡、性平,入药具有利水渗湿、益脾和胃、宁心安神之功用。现代医学研究:茯苓能增强机体免疫功能,茯苓多糖有明显的抗肿瘤及保肝脏作用。茯苓性味甘淡平,入心、肺、脾经。具有渗湿利水,健脾和胃,宁心安神的功效。可治小便不利,水肿胀满,痰饮咳逆,呕逆,恶阻,泄泻,遗精,淋浊,惊悸,健忘等症。茯苓之利水,是通过健运脾肺功能而达到的,与其它直接利水的中药不同。用于脾虚泄泻,带下茯苓既能健脾,又能渗湿,对于脾虚运化失常所致泄泻、带下,应用茯苓有标本兼顾之效,常与党参、白术、山药等配伍。有可用为补肺脾,治气虚之辅佐药。
赤芍,行瘀、止痛、凉血、消肿。主治:治瘀滞经闭、疝瘕积聚、腹痛、胁痛、衄血、血痢、肠风下血、目赤、痈肿、跌扑损伤。赤芍能清血分实热,散瘀血留滞。该品功能与丹皮相近,故常与丹皮相须为用。但丹皮清热凉血的作用较佳,既能清血分实热,又能治阴虚发热;而赤芍只能用于血分实热,以活血散瘀见长。《本经》:主邪气腹痛,除血痹,破坚积,寒热疝瘕,止痛,利小便,益气。
陈皮性温,味辛、味苦。入脾经、胃经、肺经。理气健脾,调中,燥湿,化痰。主治脾胃气滞之脘腹胀满或疼痛、消化不良。湿浊阻中之胸闷腹胀、纳呆便溏。痰湿壅肺之咳嗽气喘。用于胸脘胀满,食少吐泻,咳嗽痰多。《本草纲目》:其至百并总是取棋理气燥湿之功,同补药则补,同泻药则泻,同升药则升,同降药则降。脾乃元气之母,肺乃摄气之要,故橘皮为二经气分之要,但随所配而补泻升降也。《日用本草》:能散能泻,能温能补,能消膈气,化痰涎,和脾止嗽,通五淋。
制首乌:中药何首乌有生首乌与制首乌之分,直接切片入药为生首乌,用黑豆煮汁拌蒸后晒干入药为制首乌。二者的功用有所不同:生首乌功能解毒、消痈、润肠通便,常用于治疗瘰疬疮痈、风疹瘙痒、肠燥便秘;制首乌功能补肝肾、益精血、乌须发、强筋骨,用于血虚萎黄、眩晕耳鸣、须发早白、腰膝酸软、肢体麻木、崩漏带下、久疟体虚等。本发明所采用的制首乌是补肾益肾的佳品。
红花性温,味辛。功能主治应用于活血通径、散瘀止痛。用于经闭、痛经、恶露不行、症瘕痞块、跌打损伤。《本草汇言》:红花,破血、行血、和血、调血之药也。主胎产百病因血为患,或血烦血晕,神昏不语;或恶露抢心,脐腹绞痛;或沥浆难生,;或胞衣不落,子死腹中,是皆临产诸证,非红花不能治。若产后血晕、口噤指搦;或邪入血室,谵语发狂;或血闷内胀,僵仆如死,是皆产后诸证,非红花不能定。凡如经闭不通而寒热交作,或过期腹痛而紫黑淋漓,或跌扑损伤而气血瘀积,或疮疡痛痒而肿溃不安,是皆气血不和之证,非红花不能调,红花活血通经、消肿止痛,有抑制血栓形成、抗炎、止痛作用,具有消除肾上腺素、去甲肾上腺素的收缩血管作用,有“通利经脉”作用。
本发明具体实施方式
具体实施例1:秋天选取成熟度高,无虫害,无腐烂,无杂物的金樱子果实;分选时,选出其中的杂质,泥土石块,用振动筛和水洗槽进行分选;金樱子果质硬,采用大滚距压式的破碎机,将金樱子外皮挤破而不破碎果实的核,然后将其果核泡入60度以上的白酒或食用酒精中10-15天。
然后将浸泡好的金樱子果核加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.36的浸膏,加热浓缩至膏状,静置备用作为组分1。
将天花粉,山楂,蒲黄、冬瓜皮、蒲黄,月见草,生地、女贞子、虎杖、制首乌、绞股蓝、黄芪、茯苓、赤芍、陈皮、丹参,放入10倍量乙醇中,浸泡1-2小时,加热提取2次,每次1-2小时,合并提取液,静置后去上清液,然后放入减压浓缩罐内,减压回收乙醇,浓缩至药液浓度为0.6g生药/mL,抽滤至滤液的相对密度为20℃时1.06的浸膏,成为组分2。
将组分1和组分2合并后置入双效真空浓缩器中,浓缩至90℃时相对密度为1.05的浓缩液,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,滤液再置入双效真空浓缩器中,浓缩至每1ml含1g生药量;浓缩后的膏剂加糊精调和,紫外线消毒杀菌后装瓶。
具体实施例2:秋天选取成熟度高,无虫害,无腐烂,无杂物的金樱子果实;分选时,选出其中的杂质,泥土石块,用振动筛和水洗槽进行分选;金樱子果质硬,采用大滚距压式的破碎机,将金樱子外皮挤破而不破碎果实的核,然后将其果核5000g泡入60度以上白酒的10-15天。然后将浸泡好的金樱子果核加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.36的浸膏,加热浓缩至膏状,静置备用作为组分1。将天花粉1200g,山楂1300g,蒲黄1100g、冬瓜皮1200g、蒲黄1300g,月见草1300g,生地1100g、女贞子1200g、虎杖1200g、制首乌1200g、绞股蓝1300g、黄芪1300g、茯苓1300g、赤芍1100g、陈皮1300g、丹参1100g,将其余原料药的药放入10倍量乙醇中,浸泡1-2小时,加热提取2次,每次1-2小时,合并提取液,静置后去上清液,然后放入减压浓缩罐内,减压回收乙醇,浓缩至药液浓度为0.6g生药/mL,抽滤至滤液的相对密度为20℃时1.06的浸膏,成为组分2。将组分1和组分2合并后置入双效真空浓缩器中,浓缩至90℃时相对密度为1.05的浓缩液,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,滤液再置入双效真空浓缩器中,浓缩至每1ml含1g生药量;浓缩后的膏剂加糊精调和,紫外线消毒杀菌后装瓶。
具体实施例3:秋天选取成熟度高,无虫害,无腐烂,无杂物的金樱子果实;分选时,选出其中的杂质,泥土石块,用振动筛和水洗槽进行分选;金樱子果质硬,采用大滚距压式的破碎机,将金樱子外皮挤破而不破碎果实的核,然后将其果核4000g泡入60度以上乙醇的10-15天。然后将浸泡好的金樱子果核加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.36的浸膏,加热浓缩至膏状,静置备用作为组分1。将其余原料药天花粉1100g,山楂1100g,蒲黄1100g、冬瓜皮1200g、蒲黄1300g,月见草1300g,生地1100g、女贞子1200g、虎杖1200g、制首乌1200g、绞股蓝1300g、黄芪1300g、茯苓1300g、赤芍1100g、陈皮1100g、丹参1200g,浸泡水中12小时,然后放入提取罐加热煮沸1小时,过滤,滤液备用;滤渣加水,第二次加热,煮沸45分钟,过滤,滤液备用;滤渣再加水,第三次加热煮沸半小时,过滤;将三次滤液合在一起,用纱布过滤,残渣中加入250-60%乙醇,60℃-70℃继续浸提2h,每10min搅拌一次,纱布过滤,合并浸提液,浓缩成糊状将组分1和组分2合并后置入双效真空浓缩器中,浓缩至90℃时相对密度为1.05的浓缩液,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,滤液再置入双效真空浓缩器中,浓缩至每1ml含1g生药量;浓缩后的膏剂加糊精调和,紫外线消毒杀菌后装瓶。
具体实施例4:秋天选取成熟度高,无虫害,无腐烂,无杂物的金樱子果实;分选时,选出其中的杂质,泥土石块,用振动筛和水洗槽进行分选;金樱子果质硬,采用大滚距压式的破碎机,将金樱子外皮挤破而不破碎果实的核,然后将其果核3900g泡入60度以上白酒的10-15天。然后将浸泡好的金樱子果核加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.36的浸膏,加热浓缩至膏状,静置备用作为组分1,再将其余原料药天花粉1200g,山楂1100g,蒲黄1100g、冬瓜皮1200g、蒲黄1300g,月见草1200g,生地1100g、女贞子1200g、虎杖1200g、制首乌1200g、绞股蓝1300g、黄芪1100g、茯苓1100g、赤芍1100g、陈皮1200g、丹参1200g。将所述原料药放入粉碎机粉碎后,将颗粒物放入乙醇中加热回流提取2次,每次1~2小时,将2次提取液合并静置;将上述乙醇提取过的药渣加10倍量水加热回流提取2次,每次1~2小时,将2次提取液合并静置,将上述两种提取液合并,作为组分2;合并组分1组分2减压浓缩相对密度为70℃时1.38的滤液,回收乙醇,调入糊精或蜂蜜,紫外线杀菌后装瓶。
药理学毒性试验
一、试验材料:
(一)实验动物:小鼠NIH,体重25-28g,雌雄各半;大鼠Wistar体重130-160g,雌雄各半,大鼠、小鼠的饲料由山东医学院动物实验中心提供。
(二)受试药物:
1、本发明药物:实施例2所制的口服液,三批量等量混合物实验时用蒸馏水稀释应用。
2、阳性对照药物:金匮肾气丸,市售。
二、试验方法及结果:
(1)取体重25-28g的健康小鼠80只,雌、雄各半,按性别和体重分别分成四组,每组20只。1、2、3组服用本发明药物,剂量分别为8.6g生药/kg/d,6.4g生药/kg/d,4.2g生药/kg/d,第4组服用阳性对照药金匮肾气丸,剂量为6g生药/kg/d,连用15天。
试验结果:1、2、3组小鼠比4组小鼠性兴奋度明显增强,1、2、3组小鼠的交配次数比4组小鼠的交配次数平均每日增加3次。
试验结果表明本发明药物对中枢神经系统有明显的兴奋作用,所以本发明药物对于调节人体机能平衡、益气、补血、延缓衰老增强新陈代谢,精神疲惫,性机能减退都有治疗依据。
本发明动物急性毒性试验
一、试验材料
(一)动物小鼠NIH种雌雄各半,体重20-22g,由山东医学院动物实验室提供。
(二)受试药物:本发明所制的口服液,用蒸馏水稀释成混悬液。
二、试验方法及结果:
小鼠最大耐受量测定:取健康小鼠32只,雌雄各半,在24小时之内分三组,灌胃肠每次0.6ml/只,总重量1.8ml,相当于原生药4.0g,即100g生药/kg/d,相当于临床65公斤人的857倍。小鼠给药后按常规饲料12天未见动物死亡及未出、现毒性反应。因此证明,本发明药物无毒副作用,临床应用安全可靠。
本发明药物组合物的动物长期毒性试验
一、试验材料及方法
(一)受试药物:本发明实施例所制的口服液。
(二)实验动物,健康大鼠Wistar,体重100-130g,140只雌雄各半,按性别及体重随机分组,四组,每组35只。1、2、3组服用受试药物,剂量分别为9.6/kg/d,6.4/kg/d,3.2/kg/d。4组对照给相应体积量的蒸馏水、大鼠均灌胃肠给药,每组一次连用6个月,处死一半,余下1/2停药观察12天全部死亡。
二、测试指标
(一)一般状况包括体重、饮食、情绪、活动能量。
(二)血象检查:红细胞计数、白细胞计数、血小板计数、血象等,血红蛋白定量计数。
(三)生化检查、血清蛋白定量、胆固醇、血糖定量。
(四)病理组织检查:实验结果后取半数动物称重,断头处死,取血,同时解剖心、肝、肾、肺、脑、脾、胃肠、膀胱、肾上腺做病理组织检查。
三、试验结果:经大鼠长期毒性试验表明,用本发明大剂量灌肠六个月,对大鼠的生长、体重增加、对脑、肝、肾功能均无毒副作用。对大鼠的各组织器官、循环系统未发现损害改变,用药组与对照组比较无明显差异。说明本发明药物具有温补肾阳、益气、补血、延缓衰老增强新陈代谢等药效,无毒性。
药效学实验:
1材料和方法
1.1材料
1.1.1药物本发明口服液(制备方法2制备,制备成含生药0.9g/1ml的试药),由本院制剂科提供;盐酸二甲双胍(上海华氏制药)。
1.1.2动物昆明种小鼠96只,雌雄各半,体重(22.5±2.5)g,均由山东大学动物实验中心提供。
1.1.3试剂和仪器链脲佐菌素(STZ)(SERVER公司),购自华美公司。电子天平AB204-WO型(瑞士梅特勒-托有限公司);日立7150型全自动生化分析仪(日本)。
1.2方法
1.2.1造模与分组糖尿病:动物购回,适应性喂养1周后,随机分为正常非糖尿病组8只和实验组40只,实验组于造模前禁食12小时,造模采用STZ55mg/kg一次性腹腔注射,给药后24小时测血糖、尿糖,连续3天,尿糖定性+++以上,血糖值超过16.5mmol/L,并持续不变者,确定为糖尿病形成。
将造模成功小鼠随机分为5组,模型对照组、二甲双胍组、本发明口服液高、中、低浓度组。
高脂血症:动物购回,适应性喂养1周后,随机分为正常非高脂血症组8只和实验组40只,实验组于造模前禁食12小时,造模给予1周以上含1%胆固醇,20%猪油、2%胆酸钠、1%丙基硫嘧啶的高脂乳剂,每天1次,连续7天。将造模成功小鼠随机分为5组,模型对照组、二甲双胍组、本发明煎液高、中、低浓度组。
1.2.2给药和测定方法正常对照组和模型对照组(ig等体积的生理盐水);盐酸二甲双胍组(ig,0.20g/kg);本发明口服液组(分别每天ig本发明煎液2.0g/kg,3.0g/kg,4.0g/kg)。各组分别灌胃给药,1次/d,连续30天。末次给药前12h禁食,给药后2h,摘眼取血,用全自动生化分析仪测定血糖和血脂。
1.2.3统计学处理所有数据用“-χ±S”表示,数据采用SPSS11.5统计软件分析处理,多组间比较若方差齐性用单向方差分析,若方差不齐用秩和检验,组内前后比较用配对t检验。
2结果
2.1降糖实验由表1可知,本发明煎液高、中、低浓度组均能显著降低高血糖小鼠模型的血糖,与模型对照组比较,差异有统计学意义(P<0.05)。
表1 本发明口服液对小鼠血糖的影响(-χ±S)
注:与正常对照组比较,ΔΔP<0.01;与模型对照组比较,*P<0.05,**P<0.01;NS,生理盐水。
2.3降脂实验由表2可知,本发明口服液高、中、低浓度均能明显降低高血脂小鼠模型的TC、TG含量,与模型对照组比较,差异有统计学意义(P<0.05,P<0.01)。
表2 黄精煎液对小鼠血脂的影响(χ±S)
注:与正常对照组比较,ΔΔP<0.01;与模型对照组比较,*P<0.05,**P<0.01;NS,生理盐水。
3讨论
近年来,随着人们生活水平的不断提高,糖尿病、冠心病等疾病发病率日益增加。人的血液中,血浆内所含的脂类称为血脂,包括胆固醇、胆固醇脂、甘油三脂、磷脂和未脂化的脂酸等数种。当胆固醇、甘油三脂等均超过正常值时,则统称为高脂血症。高脂血症是动脉粥样硬化的主要发病因素。常因侵犯重要器官而引起严重的后果,如冠心病、糖尿病、脑血管意外、顽固性高血压及肾病综合症、胰腺炎、结石症、脂肪肝等。动脉硬化的发生和发展,与血脂过高有着密切的关系。中草药作用稳定,副作用少,研究具有降糖降脂作用的中草药,能为临床上治疗糖尿病、高脂血症提供更多的方法。金樱子果实风味独特,有蜂蜜味和幽香,其营养极丰富,内含糖(主要是果糖等还原糖)、柠檬酸、苹果酸、鞣质、维生素、20余种氨基酸,18种矿物元素以及树脂、皂甙等成份,尤以维生素C和还原糖含量较高。据测定,每100g鲜金樱子果肉含维生素C1009mg,含量仅次于刺梨,是鲜枣的2倍,弥猴桃的10倍,柑桔的30倍。其次,金樱子含有丰富的锌和硒,这两种元素为人体必需的具有特定保健和防癌功效的微量元素。
现代药理证明:金樱子果实口服既能促进胃液分泌帮助消化,又能使肠粘膜收缩,分泌减少而止泻;金樱子煎液对金黄色葡萄球菌、大肠杆菌、绿脓杆菌、痢疾杆菌及流感病毒均有较强的抑制作用。1、固精缩尿,涩肠止泻。金樱子中含有大量的酸性物质、皂成等,既能固精室防止男子遗精滑泄、女子带下过多,又能涩肠道,防止脾虚约束不力所致的泻痢。2、缩尿止遗。金樱子中含有大量的酸性物质和皂甙,具有制约膀脱括约肌,延长排尿时间间隔,增加每次排出尿量的作用,可用于治疗遗尿及小便频数之症。3、止咳平喘,抗痉挛。4、降血脂。金樱子中含有脂肪酸、卜谷省醇、躁质及皂式等,能降低血脂,减少脂肪在血管内的沉积,可用于治疗动脉粥样硬化症。5、抗菌消炎。研究发现,金樱子提取液可杀死金黄色葡萄球菌及大肠杆菌等,可用来治疗因金葡菌或大肠杆菌感染而致的疾病。本实验为验证其降糖、降脂作用而设,结果发现其确有明显降糖、降脂作用。
具体实施例:患者男,冯某51岁,近两年来老是困,总是睡觉,怎么睡也不够。2011年11月份检查发现血压很高。检查结果:血压:150/100汞柱。体重:74公斤。身高:168CM.血常规检查:淋巴细胞44.5参考范围20一40%。尿常规检查:尿比重1.030参考范围1.01-1.025。蛋白质+生化检验:血糖5.04(空腹)总胆固醇5.31(空腹)甘油三酯4.72高密度脂蛋白胆固醇1.54低密度脂蛋白胆固醇3.24。彩色超声医学诊断报告:高血脂、脂肪肝。曾经治疗情况和效果:正在服药降压药;苯磺酸左旋氨氯地平片、非诺贝特胶囊,不见效果。对中药口感气味比较抗拒。建议使用本发明金樱子口服液,口感好,方用:金樱子30g,天花粉11g,山楂12g,蒲黄12g、冬瓜皮11g、蒲黄13g,月见草11g,生地13g、女贞子12g、虎杖11g、制首乌13g、绞股蓝13g、黄芪11g、茯苓12g、赤芍12g、陈皮11g、丹参12g。制成口服液使用,每天2次,每次1瓶。15天为1个疗程。使用2个疗程后,甘油三酯水平过高,建议饮食严格控制,少吃脂肪、油腻食物,多吃蔬菜、水果,增加运动量、控制体重等的基础上,服用口服液就可以控制。如果血压、血脂控制理想后,仍然感觉没力气、发困,腰酸腿软等症状,继续服用中药口服液调理一段时间,恢复正常。
Claims (10)
1.一种降血脂的金樱子保健口服液,其特征在于,所述保健口服液原料药的重量份数包括:金樱子10~50份,天花粉10~20份,山楂10~20份,蒲黄10~20份、冬瓜皮10~20份、红花10~20份,月见草10~20份,生地10~20份、女贞子10~20份、虎杖10~20份、制首乌10~20份、绞股蓝10~20份、黄芪10~20份、茯苓10~20份、赤芍10~20份、陈皮10~20份、丹参10~20份。
2.根据权利要求1所述降血脂的金樱子保健口服液,其特征在于,所述保健口服液原料药的重量份数包括:金樱子10~30份,天花粉10~15份,山楂10~15份,蒲黄10~15份、冬瓜皮10~15份、红花10~15份,月见草10~15份,生地10~15份、女贞子10~15份、虎杖10~20份、制首乌10~20份、绞股蓝10~20份、黄芪10~20份、茯苓10~20份、赤芍10~20份、陈皮10~20份、丹参10~20份。
3.根据权利要求1所述降血脂的金樱子保健口服液,其特征在于,所述保健口服液原料药的重量份数包括:金樱子10~40份,天花粉10~20份,山楂10~20份,蒲黄10~20份、冬瓜皮10~20份、红花10~20份,月见草10~20份,生地10~20份、女贞子10~20份、虎杖10~15份、制首乌10~15份、绞股蓝10~15份、黄芪10~15份、茯苓10~15份、赤芍10~15份、陈皮10~15份、丹参10~15份。
4.一种如权利要求1~3中任一项所述降血脂的金樱子保健口服液,其特征在于,所述中药保健口服液的制备步骤包括:
a.金樱子的制备,作为组分1;
b.将所述其余原料药放入乙醇中加热回流提取2次,作为组分2;
c.将上述两种提取液组分1和组分2合并,浓缩后加糊精调和,消毒杀菌后制备成保健口服液剂。
5.根据权利要求4所述降血脂的金樱子保健口服液的制备方法,其特征在于,所述步骤a中,选取成熟度高,无虫害,无腐烂,无杂物的金樱子果实;分选时,选出其中的杂质,泥土石块,用振动筛和水洗槽进行分选;金樱子果质硬,采用大滚距压式的破碎机,将金樱子外皮挤破而不破碎果实的核,然后将其果核泡入60度以上的白酒或食用酒精中10-15天。
6.根据权利要求4所述降血脂的金樱子保健口服液的制备方法,其特征在于,所述步骤a中,进一步包括,将浸泡好的金樱子果核加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.36的浸膏,加热浓缩至膏状,静置备用,成组分1。
7.根据权利要求4所述降血脂的金樱子保健口服液的制备方法,其特征在于,所述步骤b中,将其余原料药的药放入10倍量乙醇中,浸泡1-2小时,加热提取2次,每次1-2小时,合并提取液,静置后去上清液,然后放入减压浓缩罐内,减压回收乙醇,浓缩至药液浓度为0.6g生药/mL,抽滤至滤液的相对密度为20℃时1.06的浸膏,成为组分2。
8.根据权利要求4所述降血脂的金樱子保健口服液的制备方法,其特征在于,所述步骤c中,将组分1和组分2合并后,置入双效真空浓缩器中,浓缩至90℃时相对密度为1.05的浓缩液,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,滤液再置入双效真空浓缩器中,浓缩至每1ml含1g生药量;浓缩后的膏剂加糊精调和,紫外线消毒杀菌后装瓶。
9.一种如权利要求1~3中任一项所述降血脂的金樱子保健口服液的的制备方法,其特征在于,其制备步骤还可以为:
a.金樱子的制备,作为组分1;
b.将所述其余原料药加水浸泡、提取3次作为组分2;
c.将组分1和组分2混合,浓缩后加适量蜂蜜调和,紫外线消毒杀菌后装瓶。
10.根据权利要求9所述降血脂的金樱子保健口服液的制备方法,其特征在于,所述步骤b中,将其余原料药浸泡水中12小时,然后放入提取罐加热煮沸1小时,过滤,滤液备用;滤渣加水,第二次加热,煮沸45分钟,过滤,滤液备用;滤渣再加水,第三次加热煮沸半小时,过滤;将三次滤液合在一起,用纱布过滤,残渣中加入50-60%乙醇,60℃-70℃继续浸提2h,每10min搅拌一次,纱布过滤,合并浸提液,浓缩成糊状成为组分2。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410424681.4A CN104208302A (zh) | 2014-08-26 | 2014-08-26 | 一种降血脂的金樱子保健口服液及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410424681.4A CN104208302A (zh) | 2014-08-26 | 2014-08-26 | 一种降血脂的金樱子保健口服液及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104208302A true CN104208302A (zh) | 2014-12-17 |
Family
ID=52090475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410424681.4A Pending CN104208302A (zh) | 2014-08-26 | 2014-08-26 | 一种降血脂的金樱子保健口服液及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104208302A (zh) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104905267A (zh) * | 2015-07-08 | 2015-09-16 | 青岛恒波仪器有限公司 | 一种决明子降血脂保健口服液及其制备方法 |
| CN104977381A (zh) * | 2015-06-01 | 2015-10-14 | 浙江工业大学 | 一种金樱子精油及其成分分析鉴定方法 |
| CN105012873A (zh) * | 2015-07-21 | 2015-11-04 | 青岛恒波仪器有限公司 | 一种降血脂的月见草保健口服液及其制备方法 |
| CN105056103A (zh) * | 2015-07-21 | 2015-11-18 | 青岛恒波仪器有限公司 | 一种辅助降血脂降胆固醇的馒头及其制备方法 |
| CN105126035A (zh) * | 2015-10-12 | 2015-12-09 | 青岛恒波仪器有限公司 | 一种养血柔肝的白芍保健口服液及其制备方法 |
| CN105126036A (zh) * | 2015-10-12 | 2015-12-09 | 青岛恒波仪器有限公司 | 一种保肝利胆的佩兰口服液及其制备方法 |
| CN105125946A (zh) * | 2015-10-12 | 2015-12-09 | 青岛恒波仪器有限公司 | 一种清心除烦的栀子口服液及其制备方法 |
| CN105169277A (zh) * | 2015-10-12 | 2015-12-23 | 青岛恒波仪器有限公司 | 一种保肝利胆的栀子口服液及其制备方法 |
| CN105434858A (zh) * | 2015-12-31 | 2016-03-30 | 青岛安倍康生物医药技术有限公司 | 中药祛斑口服液制作方法及其口服液 |
| CN105434857A (zh) * | 2015-12-31 | 2016-03-30 | 青岛安倍康生物医药技术有限公司 | 一种疏肝化瘀祛斑的佛手保健口服液及其制备方法 |
| CN105535571A (zh) * | 2015-12-04 | 2016-05-04 | 青岛安倍康生物医药技术有限公司 | 一种排毒除湿,保肝利胆的车前子口服液及其制备方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1311023A (zh) * | 2001-02-27 | 2001-09-05 | 周文志 | 洗髓阀毛抗栓净血的药物及制备方法 |
| CN101524502A (zh) * | 2008-03-06 | 2009-09-09 | 北京中科仁和科技有限公司 | 一种用于治疗降血脂的中药组合物 |
| CN102188560A (zh) * | 2010-03-08 | 2011-09-21 | 张锡林 | 中药治疗高血脂 |
| CN103805437A (zh) * | 2014-02-27 | 2014-05-21 | 哈尔滨膳宝酒业有限公司 | 一种蓝莓降血脂酒及生产方法 |
-
2014
- 2014-08-26 CN CN201410424681.4A patent/CN104208302A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1311023A (zh) * | 2001-02-27 | 2001-09-05 | 周文志 | 洗髓阀毛抗栓净血的药物及制备方法 |
| CN101524502A (zh) * | 2008-03-06 | 2009-09-09 | 北京中科仁和科技有限公司 | 一种用于治疗降血脂的中药组合物 |
| CN102188560A (zh) * | 2010-03-08 | 2011-09-21 | 张锡林 | 中药治疗高血脂 |
| CN103805437A (zh) * | 2014-02-27 | 2014-05-21 | 哈尔滨膳宝酒业有限公司 | 一种蓝莓降血脂酒及生产方法 |
Non-Patent Citations (2)
| Title |
|---|
| 侯士良: "《中药八百种详解》", 31 January 2009, 河南科学技术出版社 * |
| 庄瑞丰: "中药降血脂作用研究进展", 《河北医药》 * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104977381A (zh) * | 2015-06-01 | 2015-10-14 | 浙江工业大学 | 一种金樱子精油及其成分分析鉴定方法 |
| CN104905267A (zh) * | 2015-07-08 | 2015-09-16 | 青岛恒波仪器有限公司 | 一种决明子降血脂保健口服液及其制备方法 |
| CN105012873A (zh) * | 2015-07-21 | 2015-11-04 | 青岛恒波仪器有限公司 | 一种降血脂的月见草保健口服液及其制备方法 |
| CN105056103A (zh) * | 2015-07-21 | 2015-11-18 | 青岛恒波仪器有限公司 | 一种辅助降血脂降胆固醇的馒头及其制备方法 |
| CN105126035A (zh) * | 2015-10-12 | 2015-12-09 | 青岛恒波仪器有限公司 | 一种养血柔肝的白芍保健口服液及其制备方法 |
| CN105126036A (zh) * | 2015-10-12 | 2015-12-09 | 青岛恒波仪器有限公司 | 一种保肝利胆的佩兰口服液及其制备方法 |
| CN105125946A (zh) * | 2015-10-12 | 2015-12-09 | 青岛恒波仪器有限公司 | 一种清心除烦的栀子口服液及其制备方法 |
| CN105169277A (zh) * | 2015-10-12 | 2015-12-23 | 青岛恒波仪器有限公司 | 一种保肝利胆的栀子口服液及其制备方法 |
| CN105535571A (zh) * | 2015-12-04 | 2016-05-04 | 青岛安倍康生物医药技术有限公司 | 一种排毒除湿,保肝利胆的车前子口服液及其制备方法 |
| CN105434858A (zh) * | 2015-12-31 | 2016-03-30 | 青岛安倍康生物医药技术有限公司 | 中药祛斑口服液制作方法及其口服液 |
| CN105434857A (zh) * | 2015-12-31 | 2016-03-30 | 青岛安倍康生物医药技术有限公司 | 一种疏肝化瘀祛斑的佛手保健口服液及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103053748B (zh) | 一种葛根降脂降糖保健茶及其制备方法 | |
| CN104208302A (zh) | 一种降血脂的金樱子保健口服液及其制备方法 | |
| CN103749822B (zh) | 一种女贞子降压降脂保健茶及其制备方法 | |
| CN103719494B (zh) | 一种牛蒡子通便润肠保健茶及其制备方法 | |
| CN105749179A (zh) | 治疗代谢综合征的中药组合物 | |
| CN102755596B (zh) | 一种治疗痰湿型乳腺增生的中药及制备方法 | |
| CN102772737B (zh) | 用于治疗肝硬化纤维化的中药组合物及其制备方法 | |
| CN104666579A (zh) | 一种治疗膝关节滑膜炎的中药组合物及其制备方法 | |
| CN104958607A (zh) | 一种治疗妇女更年期灼口综合征的中药组合物及方法 | |
| CN104206594A (zh) | 一种降压降脂的桑寄生保健茶及其制备方法 | |
| CN104305205A (zh) | 一种提高免疫力的菟丝子口服液及其制备方法 | |
| CN103749824B (zh) | 一种绞股蓝降糖降压保健茶及其制备方法 | |
| CN101607051A (zh) | 一种中药减肥组合物及其制备方法 | |
| CN104905267A (zh) | 一种决明子降血脂保健口服液及其制备方法 | |
| CN105194421A (zh) | 一种夏枯草降血脂保健口服液及其制备方法 | |
| CN105124078A (zh) | 一种栀子花降糖降脂保健茶及其制备方法 | |
| CN103749819B (zh) | 一种降糖降脂的山茱萸保健茶及其制备方法 | |
| CN102846824B (zh) | 一种治疗寒湿血瘀阻络型糖尿病足的中药组合物及其制备方法 | |
| CN104206595A (zh) | 一种降脂降糖的地骨皮保健茶及其制备方法 | |
| CN105012873A (zh) | 一种降血脂的月见草保健口服液及其制备方法 | |
| CN103933538A (zh) | 用于治疗脾肾阳虚型肝硬化腹水的药物及其制备方法 | |
| CN103705860B (zh) | 一种治疗婴幼儿黄疸的中药组合物及其制备方法 | |
| CN105343593A (zh) | 一种降压降脂的夏枯草保健口服液及其制备方法 | |
| CN105056103A (zh) | 一种辅助降血脂降胆固醇的馒头及其制备方法 | |
| CN105394282A (zh) | 一种可降压降糖降脂的葛根保健茶 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20141217 |